Clinical Trial

Magnesium Sulfate and Trigger Points

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 16, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The patients will be randomly assigned to one of the two groups according to the treatment method: group I (masseter group) and group II (masseter \&sternocleidomastoid group) where each patient will be injected 0.5ml in each trigger point (TrPs) of magnesium sulphate according to the treatment group by the same operator. The treatment method for TrPs will be the primary predictor variable. Patients will be examined at the following intervals: during diagnosis, 1-month, 3-months, and 6-months post-injection. The participated patients will be assessed using pain score measured on a 10-point visual analogue scale (VAS), the 0 indicating no pain and 10 indicating the worst pain ever
Trial Details
NCT Number NCT06975813
Lead Sponsor Fayoum University
Conditions Myofascial Pain Syndrome
Enrollment 30 participants
Start Date 2025-06-01
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-01-27 (estimated)
Updated on ClinicalTrials.gov 2025-05-16